Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


In Brief: Schering/Orion's Fareston

Executive Summary

Schering/Orion's Fareston: "Approvable" as of Jan. 3 for treating advanced breast cancer in postmenopausal women with estrogen receptor-positive tumors or receptor-unknown tumors. The oral anti-estrogen toremifene citrate was unanimously recommended for approval by an FDA advisory committee Oct. 16. Schering-Plough has marketing rights to Fareston in the U.S. through an agreement with Orion-Farmos, the Finnish drug manufacturer that submitted the NDA in December 1994...



Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts